F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, Philadelphia, Pennsylvania.
F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, Perelman School of Medicine at the University of Pennsylvania, 305 Stellar-Chance Laboratory, Philadelphia, Pennsylvania; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.
Am J Pathol. 2019 Sep;189(9):1814-1830. doi: 10.1016/j.ajpath.2019.05.022. Epub 2019 Jul 6.
The liver secretes hepcidin (Hepc) into the bloodstream to reduce blood iron levels. Hepc accomplishes this by triggering degradation of the only known cellular iron exporter ferroportin in the gut, macrophages, and liver. We previously demonstrated that systemic Hepc knockout (HepcKO) mice, which have high serum iron, develop retinal iron overload and degeneration. However, it was unclear whether this is caused by high blood iron levels or, alternatively, retinal iron influx that would normally be regulated by retina-produced Hepc. To address this question, retinas of liver-specific and retina-specific HepcKO mice were studied. Liver-specific HepcKO mice had elevated blood and retinal pigment epithelium (RPE) iron levels and increased free (labile) iron levels in the retina, despite an intact blood-retinal barrier. This led to RPE hypertrophy associated with lipofuscin-laden lysosome accumulation. Photoreceptors also degenerated focally. In contrast, there was no change in retinal or RPE iron levels or degeneration in the retina-specific HepcKO mice. These data indicate that high blood iron levels can lead to retinal iron accumulation and degeneration. High blood iron levels can occur in patients with hereditary hemochromatosis or result from use of iron supplements or multiple blood transfusions. Our results suggest that high blood iron levels may cause or exacerbate retinal disease.
肝脏将铁调素 (Hepc) 分泌到血液中,以降低血液中的铁含量。Hepc 通过触发肠道、巨噬细胞和肝脏中唯一已知的细胞铁输出蛋白 Ferroportin 的降解来实现这一点。我们之前的研究表明,血清铁含量高的全身性 Hepc 基因敲除 (HepcKO) 小鼠会发生视网膜铁过载和变性。然而,目前尚不清楚这是由高血液铁含量引起的,还是由通常受视网膜产生的 Hepc 调节的视网膜铁内流引起的。为了解决这个问题,我们研究了肝脏特异性和视网膜特异性 HepcKO 小鼠的视网膜。肝脏特异性 HepcKO 小鼠的血液和视网膜色素上皮 (RPE) 铁含量升高,视网膜中的游离(不稳定)铁含量增加,尽管血视网膜屏障完整。这导致与脂褐素负荷溶酶体积累相关的 RPE 肥大。感光细胞也出现局灶性变性。相比之下,视网膜特异性 HepcKO 小鼠的视网膜或 RPE 铁含量或变性没有变化。这些数据表明,高血液铁含量可导致视网膜铁积累和变性。遗传性血色素沉着症患者可能会出现高血液铁含量,或者由于使用铁补充剂或多次输血而导致高血液铁含量。我们的研究结果表明,高血液铁含量可能导致或加重视网膜疾病。